Clover Health Appoints Robert Torricelli and Dr. Brian Miller to Board

What Happened Clover Health Investments, Corp. (CLOV) filed an 8-K on September 24, 2026 reporting that, on September 22, 2026, its Board appointed Senator Robert G. Torricelli as a Class I director and Dr. Brian J. Miller, M.D., M.B.A., M.P.H., as a Class III director. Senator Torricelli was named to the Board’s Audit Committee and Dr. Miller was named to the Clinical Committee. These appointments fill two previously disclosed board vacancies and bring the Board to nine directors. The company attached a press release dated September 24, 2026 as Exhibit 99.1.

Key Details

• Filing: Form 8-K filed September 24, 2026 (Item 5.02 disclosure of director appointments).
• Appointment dates: Both directors were appointed effective September 22, 2026.
• Committee assignments: Torricelli → Audit Committee; Miller → Clinical Committee.
• Board size: Appointments increase the Board to nine directors, filling two prior vacancies.

Why It Matters Board composition can affect governance, oversight and strategic direction. Adding a former U.S. Senator with Audit Committee duties may strengthen regulatory and financial oversight, while adding a physician-executive to the Clinical Committee may bolster clinical and medical-policy expertise—both relevant to Clover’s healthcare business. Investors should note these are governance changes disclosed in an 8-K; no compensation or operational changes were detailed in this filing.